• Health

    Bausch, Teva face lawsuit for delay in generic version of Xifaxan

    AnyFans Posted on

    Bausch, Teva face lawsuit for delay in generic version of Xifaxan

    Sep. 23, 2025 2:17 PM ETTeva Pharmaceutical Industries Limited (TEVA) Stock, BHC StockBy: Nilanjana Basu, SA News Editor
    Comments
    Bausch Health (NYSE:BHC) and Teva (NYSE:TEVA) are facing a lawsuit accusing them of conspiring to delay the release of a cheaper generic version of Bausch’s diarrhea drug, Xifaxan, keeping prices artificially high, according to a Reuters article.
    The case, filed in
    Recommended For You
    More Trending News
    Related Stocks
    SymbolLast Price% Chg
    TEVA
    TEVA
    —
    BHC
    BHC
    —
    1D
    5D
    1M
    6M
    1Y
    5Y
    10Y
    Trending Analysis
    Trending News

    You Might Also Like